Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:6734678.
doi: 10.1155/2016/6734678. Epub 2016 Dec 12.

Parkinson's Disease and Cognitive Impairment

Affiliations
Review

Parkinson's Disease and Cognitive Impairment

Yang Yang et al. Parkinsons Dis. 2016.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease primarily characterized by the hallmarks of motor symptoms, such as tremor, bradykinesia, rigidity, and postural instability. However, through clinical investigations in patients and experimental findings in animal models of Parkinson's disease for years, it is now well recognized that Parkinson's disease is more than just a motor-deficit disorder. The majority of Parkinson's disease patients suffer from nonmotor disabilities, for instance, cognitive impairment, autonomic dysfunction, sensory dysfunction, and sleep disorder. So far, anti-PD prescriptions and surgical treatments have been mainly focusing on motor dysfunctions, leaving cognitive impairment a marginal clinical field. Within the nonmotor symptoms, cognitive impairment is one of the most common and significant aspects of Parkinson's disease, and cognitive deficits such as dysexecutive syndrome and visuospatial disturbances could seriously affect the quality of life, reduce life expectancy, prolong the duration of hospitalization, and therefore increase burdens of caregiver and medical costs. In this review, we have done a retrospective study of the recent related researches on epidemiology, clinical manifestation and diagnosis, genetics, and potential treatment of cognitive deficits in Parkinson's disease, aiming to provide a summary of cognitive impairment in Parkinson's disease and make it easy for clinicians to tackle this challenging issue in their future practice.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Similar articles

Cited by

References

    1. Litvan I., Bhatia K. P., Burn D. J., et al. SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Movement Disorders. 2003;18(5):467–486. doi: 10.1002/mds.10459. - DOI - PubMed
    1. Buter T. C., van den Hout A., Matthews F. E., Larsen J. P., Brayne C., Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017–1022. doi: 10.1212/01.wnl.0000306632.43729.24. - DOI - PubMed
    1. Hely M. A., Reid W. G. J., Adena M. A., Halliday G. M., Morris J. G. L. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement Disorders. 2008;23(6):837–844. doi: 10.1002/mds.21956. - DOI - PubMed
    1. Aarsland D., Andersen K., Larsen J. P., Lolk A., Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Archives of Neurology. 2003;60(3):387–392. doi: 10.1001/archneur.60.3.387. - DOI - PubMed
    1. Levy G., Tang M.-X., Louis E. D., et al. The association of incident dementia with mortality in PD. Neurology. 2002;59(11):1708–1713. doi: 10.1212/01.WNL.0000036610.36834.E0. - DOI - PubMed

LinkOut - more resources